Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
SciClone Pharmaceuticals
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00039962CT.gov Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatitis C Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Thymosins Thymalfasin (this asset) | SciClone Pharmaceuticals | P3 | BB · 64 |
| Veruprevir | AbbVie | P4 | A |
| Daclatasvir | MTI University | P4 | A |
| Velpatasvir | Peking University People's Hospital | P4 | A |
| Pibrentasvir | AbbVie | P3 | A |
| Glecaprevir | AbbVie | P3 | A |
| Sofosbuvir | Peking University People's Hospital | P4 | A |
| Ombitasvir | AbbVie | P3 | A |
| Dasabuvir | AbbVie | P3 | A |
+42 more in the Hepatitis C Virus Infection cohort
Other indications for Thymosins Thymalfasin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Hepatitis C Virus Infection | — | P3 | BB · 64 |
| Non-Small Cell Lung Carcinoma | — | P2 | B · 60 |
| Hepatocellular Carcinoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Thymosins Thymalfasin in Hepatitis C Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/thymosins-thymalfasin-hepatitis-c-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →